LPTX (LPTX)
Leap Therapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
USLeap Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing treatments for various cancers. At the forefront of its pipeline is DKN-01, a monoclonal antibody designed to block Dickkopf-related protein 1 (DKK1). This investigational therapy is currently undergoing several clinical trials, targeting a range of malignancies such as esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics has also forged an option and licensing partnership with BeiGene, Ltd., granting them rights to develop and market DKN-01 across Asia (excluding Japan), Australia, and New Zealand. Established in 2011, the company initially operated as HealthCare Pharmaceuticals, Inc., before rebranding to Leap Therapeutics, Inc. in November 2015.
Its corporate headquarters are situated in Cambridge, Massachusetts.
Leadership
Augustine Lawlor
Chief Operating Officer
Christian Richard
Audit Committee Member
Christine Granfield
Vice President, Head of Regulatory Affairs and Quality
Christopher K. Mirabelli, PhD
Chairman of the Board
Employees
52
Country
US
Sector
Healthcare
Website
leaptx.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 LAWLOR AUGUSTINE | Chief Operating Officer | Automatic Sell | 7.8K | $2.5K | Mar 28, 2025 |
 ONSI DOUGLAS E | CEO,CFO,Pres.,GC,Treas.&Sec. | Option Exercise | 32.5K | -- | Mar 28, 2025 |
 Granfield Christine | VP, Head of Reg Affairs/Qual | Option Exercise | 22.5K | -- | Mar 28, 2025 |
| Granfield Christine | VP, Head of Reg Affairs/Qual | Automatic Sell | 6.6K | $2.1K | Mar 28, 2025 |
 Baum Jason | Chief Scientific Officer | Option Exercise | 22.5K | -- | Mar 28, 2025 |
| Baum Jason | Chief Scientific Officer | Automatic Sell | 6.6K | $2.1K | Mar 28, 2025 |
| Name | Shares | % | Source |
|---|---|---|---|
VANGUARD CAPITAL MANAGEMENT LLC | 3.9M | -- | 13F |
BlackRock, Inc. | 2.6M | -- | 13F |
JANE STREET GROUP, LLC | 1.7M | -- | 13F |
GEODE CAPITAL MANAGEMENT, LLC | 1.2M | -- | 13F |
UBS Group AG | 1.1M | -- | 13F |
CITADEL ADVISORS LLC | 836.2K | -- | 13F |
XTX Topco Ltd | 638.3K | -- | 13F |
VANGUARD FIDUCIARY TRUST CO | 571.3K | -- | 13F |
STATE STREET CORP | 516.1K | -- | 13F |
SLT Holdings LLC | 346.0K | -- | 13F |
Insiders
- LAWLOR AUGUSTINEChief Operating Officer
- ONSI DOUGLAS ECEO,CFO,Pres.,GC,Treas.&Sec.
- Granfield ChristineVP, Head of Reg Affairs/Qual
- Baum JasonChief Scientific Officer
- O'Mahony John MarkChief Manufacturing Officer
- Mirabelli ChristopherDirector
- Sirard CynthiaChief Medical Officer
- CAVANAUGH JAMES HDirector
- Mashiach NissimDirector
- Richard Christian MDirector
US30d Avg
--
60d Avg
--
90d Avg
--